Misplaced Pages

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 12:27, 10 December 2011 (Updating {{drugbox}} (no changed fields - added verified revid - updated 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmac...). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

8A-PDHQ

Identifiers
IUPAC name 8a-phenyldecahydroquinoline
CAS Number	131556-11-1
PubChem CID	131397
ChemSpider	116144
CompTox Dashboard (EPA)	DTXSID40927262
Chemical and physical data
Formula	C15H21N
Molar mass	215.3339 g/mol g·mol
3D model (JSmol)	Interactive image
SMILES c1ccccc1C32NCCCC2CCCC3
InChI InChI=1S/C15H21N/c1-2-7-13(8-3-1)15-11-5-4-9-14(15)10-6-12-16-15/h1-3,7-8,14,16H,4-6,9-12H2 Key:QEXADSRMRUUCQJ-UHFFFAOYSA-N
(verify)

8a-Phenyldecahydroquinoline (8A-PDHQ) is a high affinity NMDA antagonist. It is a structural analog of Phencyclidine with slightly lower binding affinity than the parent compound. (-)-8a-Phenyldecahydroquinoline has an in vivo potency comparable to that of (+)-MK-801.

References

1. Chen C, Kozikowski AP, Wood PL, Reynolds IJ, Ball RG, Pang YP (1992). "Synthesis and biological activity of 8a-phenyldecahydroquinolines as probes of PCP's binding conformation. A new PCP-like compound with increased in vivo potency". J Med Chem. 35 (9): 1634–8. doi:10.1021/jm00087a020. PMID 1315871.{{cite journal}}: CS1 maint: multiple names: authors list (link)
2. Elhallaoui M, Laguerre M, Carpy A, Ouazzani FC (2002). "Molecular modeling of noncompetitive antagonists of the NMDA receptor: proposal of a pharmacophore and a description of the interaction mode". J Mol Model. 8 (2): 65–72. doi:10.1007/s00894-001-0067-4. PMID 12032600.{{cite journal}}: CS1 maint: multiple names: authors list (link)

This hallucinogen-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Dissociative drugs
• NMDA receptor antagonists
• Quinolines
• Hallucinogen stubs